Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting scheduled for the second quarter of 2026 ~~ Progressing AMT-130 ...
Same-restaurant sales growth of 2.8% Total revenues increased 17.3% Net loss of $(2.7) million and Adjusted EBITDA of $27.8 million 16 new ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need ...
Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the first quarter ended March 31, 2026. “We started the year ...
Ball Corporation today reported first quarter 2026 results.U.S. GAAP Financial Performance On a U.S. GAAP basis, the company reported first quarter 2026 net earnings attributable to the corporation of ...
Q32 Bio Inc. ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results